Zai Lab Ltd (ZLAB) stock
ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30390% above fair value
$22.11−1.42 (-6.03%)
Close on Nov 18, 2026Market cap $3.43BP/E –Yield –
Zai Lab shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Zai Lab's shares outstanding was 1.12B at Jun 30, 2026. For fiscal 2025 it was 1.10B, up 10.7% from the year before. Over ten years it grew 28.8% a year on average. The highest annual figure on record is 1.10B in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1.10B | +10.7% |
| FY2024 | Dec 31, 2024 | 989M | +2.4% |
| FY2023 | Dec 31, 2023 | 966M | +0.9% |
| FY2022 | Dec 31, 2022 | 958M | +3.0% |
| FY2021 | Dec 31, 2021 | 930M | +19.7% |
| FY2020 | Dec 31, 2020 | 777M | +20.7% |
| FY2019 | Dec 31, 2019 | 644M | +22.4% |
| FY2018 | Dec 31, 2018 | 526M | +141.9% |
| FY2017 | Dec 31, 2017 | 218M | +130.5% |
| FY2016 | Dec 31, 2016 | 94M | +8.6% |
| FY2015 | Dec 31, 2015 | 87M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 1.12B | +2.3% |
| Q1 FY2026 | Mar 31, 2026 | 1.11B | +2.5% |
| Q4 FY2025 | Dec 31, 2025 | 1.11B | +7.7% |
| Q3 FY2025 | Sep 30, 2025 | 1.10B | +12.3% |
| Q2 FY2025 | Jun 30, 2025 | 1.09B | +11.9% |
| Q1 FY2025 | Mar 31, 2025 | 1.08B | +11.1% |
| Q4 FY2024 | Dec 31, 2024 | 1.03B | +5.8% |
| Q3 FY2024 | Sep 30, 2024 | 982M | +1.3% |
| Q2 FY2024 | Jun 30, 2024 | 976M | +1.2% |
| Q1 FY2024 | Mar 31, 2024 | 973M | +1.2% |
| Q4 FY2023 | Dec 31, 2023 | 970M | +1.1% |
| Q3 FY2023 | Sep 30, 2023 | 969M | +1.0% |
| Q2 FY2023 | Jun 30, 2023 | 965M | +0.7% |
| Q1 FY2023 | Mar 31, 2023 | 961M | +0.6% |
| Q4 FY2022 | Dec 31, 2022 | 960M | +0.6% |
| Q3 FY2022 | Sep 30, 2022 | 959M | +0.9% |
| Q2 FY2022 | Jun 30, 2022 | 958M | +2.9% |
| Q1 FY2022 | Mar 31, 2022 | 955M | +8.1% |
| Q4 FY2021 | Dec 31, 2021 | 954M | +9.0% |
| Q3 FY2021 | Sep 30, 2021 | 950M | +26.0% |
| Q2 FY2021 | Jun 30, 2021 | 930M | +24.5% |
| Q1 FY2021 | Mar 31, 2021 | 884M | +21.1% |
| Q4 FY2020 | Dec 31, 2020 | 875M | +28.9% |
| Q3 FY2020 | Sep 30, 2020 | 754M | +11.4% |
| Q2 FY2020 | Jun 30, 2020 | 747M | +28.8% |
| Q1 FY2020 | Mar 31, 2020 | 730M | – |
| Q4 FY2019 | Dec 31, 2019 | 679M | – |
| Q3 FY2019 | Sep 30, 2019 | 677M | – |
| Q4 FY2018 | Dec 31, 2018 | 580M | – |
See a number that looks wrong?